Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992;30(3):207-11.
doi: 10.1007/BF00686313.

Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients

Affiliations

Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients

M J Tasso et al. Cancer Chemother Pharmacol. 1992.

Abstract

The pharmacokinetics and metabolism of cyclophosphamide were studied in nine paediatric patients. Plasma samples were obtained from eight subjects and urine was collected from six children during a 24-h period after drug administration. Cyclophosphamide and its major metabolites phosphoramide mustard (PM), carboxyphosphamide (CX), dechloroethylcyclophosphamide (DCCP) and 4-ketocyclophosphamide (KETO) were determined in plasma and urine using high-performance thin-layer chromatography-photographic densitometry (HPTLC-PD). Cyclophosphamide (CP) was nearly, if not completely, cleared from plasma by 24 h after its administration. The plasma half-life of CP ranged from 2.15 to 8.15 h; it decreased following higher doses and was shorter than that previously reported for adult patients. Both the apparent volume of distribution (0.49 +/- 1.4 l/kg) and the total body clearance (2.14 +/- 1.4 l m-2 h-1) increased with increasing dose. Renal clearance ranged between 0.12 and 0.58 l/h (mean, 0.43 +/- 0.19 l/h). Between 5.4% and 86.1% of the total delivered dose was recovered as unchanged drug in the urine. The major metabolites identified in plasma and urine were PM and CX. One patient appeared to be deficient in CX formation. This study suggests that there is interpatient variability in the pharmacokinetics and metabolism of CP in paediatric patients. The shorter half-life and higher clearance as compared with adult values indicate faster CP metabolism in children.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cancer Chemother Pharmacol. 1983;10(3):192-3 - PubMed
    1. Br J Clin Pharmacol. 1980 Sep;10(3):281-5 - PubMed
    1. Br J Clin Pharmacol. 1984 Jul;18(1):106-7 - PubMed
    1. Ann Intern Med. 1974 Apr;80(4):531-40 - PubMed
    1. Biochem Pharmacol. 1988 Jul 15;37(14):2781-90 - PubMed

Publication types

Substances

LinkOut - more resources